Trials / Completed
CompletedNCT02200822
Systematic Withdrawal of Neurohumoral Blocker Therapy in Optimally Responding CRT Patients
Systematic Withdrawal of Neurohumoral Blocker Therapy in Optimally Responding Patients to Cardiac Resynchronization Therapy: the STOP-CRT Trial
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 80 (actual)
- Sponsor
- Hasselt University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to demonstrate that in patients with recuperated/normalized left ventricular function, defined as an ejection fraction (EF) ≥ 50%, after implantation of cardiac resynchronization therapy, device treatment is sufficient and neurohumoral blocker therapy can safely be withdrawn
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | beta blockers | |
| DRUG | RAAS blockers | RAAS blockers (combination of ACE-I/ARB and a mineralocorticoid receptor antagonist) |
Timeline
- Start date
- 2014-07-01
- Primary completion
- 2019-02-01
- Completion
- 2019-02-01
- First posted
- 2014-07-25
- Last updated
- 2019-08-01
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT02200822. Inclusion in this directory is not an endorsement.